Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis

详细信息    查看全文

• 作者：Zhu Lan ; Dan Fu ; Xiuzhang Yu ; Mingrong Xi
• 关键词：Ovarian cancer ; Osteopontin ; Cancer antigen 125 ; Diagnosis
• 刊名：Familial Cancer
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：15
• 期：2
• 页码：221-230
• 全文大小：1,082 KB
• 参考文献：1.Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236CrossRef PubMed
  2.Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin. 64:9–29CrossRef PubMed
  3.American Cancer Society (2014) Cancer facts and figures 2014. American Cancer Society, Atlanta
  4.Zhen S, Bian LH, Chang LL, Gao X (2014) Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis. Mol Clin Oncol 2(4):559–566PubMed PubMedCentral
  5.Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374(9698):1371–1382CrossRef PubMed
  6.Baldwin LA, Huang B, Miller RW et al (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120:612–618CrossRef PubMed
  7.Li F, Tie R, Chang K et al (2012) Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer 12:258CrossRef PubMed PubMedCentral
  8.Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(Suppl 3):274–281CrossRef PubMed
  9.Niloff JM, Klug TL, Schaetzl E et al (1984) Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148:1057–1058CrossRef PubMed
  10.Yurkovetsky Z, Skates S, Lomakin A et al (2010) Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28:2159–2166CrossRef PubMed PubMedCentral
  11.Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2011) Pre-and post-translational regulation of osteopontin in cancer. J. Cell Commun Signal 5:111CrossRef PubMed PubMedCentral
  12.Fedarko NS, Jain A, Karadag A et al (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7(12):4060–4066PubMed
  13.Koopmann J, Fedarko NS, Jain A et al (2004) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev 13(3):487–491
  14.Wong KK, Cheng RS, Mok SC (2001) Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30:670–675PubMed
  15.Matsuura M, Suzuki T, Saito T (2007) Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci (in press)
  16.Bao L, Sakaguchi H, Fujimoto J et al (2007) Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 14:373–381CrossRef PubMed
  17.Kim JH, Skates SJ, Uede T et al (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13):1671–1679CrossRef PubMed
  18.Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536CrossRef PubMed
  19.Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRef PubMed
  20.Li MJ, Yang YQ, Peng CX et al (2013) Significance of OPN combined with CA125 in early diagnosis of ovarian cancer. Prog Mod Biomed 13(04):691–693
  21.Zhao YH, Zhang Q, Hao F (2012) The diagnostic values of combined determination of serum tumor markers HE4, OPN and CA125 levels in patients with epithelial ovarian cancer. J Med Theor Pract 25(23):2283–2285
  22.Fan JB, Zhang GL, Wu J et al (2012) Clinical value of b-type ultrasonography combined with serum levels of OPN and CA125 in the early diagnosis of ovarian cancer. J Shanxi Med Univ 43(03):225–228
  23.Yang B, Jia J, Shi DM, Li J, Chen I (2012) Evaluation of selected serum proteins CA125 and OPN as diagnosis of ovarian cancer. Prog Mod Biomed 12(9):1742–1744
  24.Yang JH, Liu JH, Shun ZP (2007) Detection of osteopontin and CA125 in patients with ovarian cancer and its clinical significance. Chin J Fam Plan 139(5):303–305
  25.Wu FJ, Guan S, Huang BY et al (2009) Detection of osteopontin and CA125 in patients with ovarian cancer and its clinical significance. Chin J Lab Diagn. 13(9):1170–1172
  26.Zhou YH, Wu XF (2008) Significance of OPN combined with CA125 in diagnosis of epithelial ovarian cancer. J Clin Exp Med 07(04):35–37
  27.Zhang YJ, Yuan ZF (2013) Expression and significance ofHE4, OPN and c-OPN in carcinoma, ascites, serum and urine in patients with epithelial ovarian cancer. Matern Child Healthc China 28(14):2290–2293
  28.Wang Y, Wang J, Zhang ZM et al (2013) Clinical significance of serum OPN, HE4 and CA125 levels in patients with ovarian cancer. Prog Mod Biomed 13(30):5937–5940
  29.Mor G, Visintin I, Lai Y et al (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102:7677–7682CrossRef PubMed PubMedCentral
  30.Nakae M, Iwamoto I, Fujino T et al (2006) Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 32(3):309–314CrossRef PubMed
  31.Meinhold-Heerlein I, Bauerschlag D, Zhou Y et al (2007) An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 13:458–466CrossRef PubMed
  32.Moore RG, Brown AK, Miller MC et al (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402–408CrossRef PubMed
  33.Bandiera E, Zanotti L, Fabricio AS et al (2013) Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 51:1815–1824CrossRef PubMed
  34.Moszynski R, Szubert S, Szpurek D, Michalak S, Sajdak S (2013) Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res 39(11):1518–1525CrossRef PubMed
  35.Milivojevic M, Boskovic V, Atanackovic J et al (2013) Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma. Eur J Gynaecol Oncol 34:83–85PubMed
  36.Yan Y, Liu Z, Liu DQ et al (2013) Combination of serum CA125, HE4 and OPN in the diagnosis of ovarian cancer. Chin J Clin Med 20(04):440–442
  37.Zamora J, Abraira V, Muriel A et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31CrossRef PubMed PubMedCentral
  38.Wang YD, Chen H, Liu HQ, Hao M (2014) Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis. Tumour Biol 35(12):11799–11808CrossRef PubMed
  39.Jaeschke R, Guyatt G, Lijmer J (2002) Diagnostic tests. In: Guyatt G, Rennie D (eds) Users guides to the medical literature: a manual for evidence-based clinical practice. AMA Press, Chicago, pp 121–140
  40.Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM (2010) Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 104(1):149–156CrossRef PubMed
  41.Medeiros LR, Rosa DD, da Rosa MI et al (2009) Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 142(2):99–105CrossRef PubMed
  42.Visintin I, Feng Z, Longton G et al (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14:1065–1072CrossRef PubMed
  43.Vrzalova J, Prazakova M, Novotny Z et al (2009) Test of ovarian cancer multiplex xMAP technology panel. Anticancer Res 29:573–576PubMed
  44.Lu D, Kuhn E, Bristow RE et al (2011) Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 122:560–566CrossRef PubMed PubMedCentral
  45.He G, Holcroft CA, Beauchamp MC et al (2012) Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Cancer 34:567–574CrossRef
  46.Fredriksson S, Horecka J, Brustugun OT et al (2008) Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem 54:582–589CrossRef PubMed
  47.de Groot JA, Bossuyt PM, Reitsma JB et al (2011) Verification problems in diagnostic accuracy studies: consequences and solutions. BMJ 343:d4770. doi:10.​1136/​bmj.​d4770 CrossRef PubMed
  
• 作者单位：Zhu Lan (1)
  Dan Fu (2)
  Xiuzhang Yu (1)
  Mingrong Xi (1)
  
  1. Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Number 20, 3rd Section, South Renmin Road, Chengdu, 610041, Sichuan, China
  2. Department of Medical Informatics, West China School of Medicine, Sichuan University, Number 16, 3rd Section, South Renmin Road, Chengdu, 610041, Sichuan, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Human Genetics
  Epidemiology
  
• 出版者：Springer Netherlands
• ISSN：1573-7292

文摘

Osteopontin (OPN) is currently one of the most studied serum biomarkers of ovarian cancer (OC). This meta-analysis aims to ascertain whether OPN is a useful diagnostic biomarker for OC and determine the overall diagnostic accuracy of OPN measurement when combined with cancer antigen 125 (CA125). A systematic literature search was conducted in Cochrane Library, PubMed, EMBASE, CBM, and China National Knowledge Infrastructure databases. Information was independently extracted by two investigators. The Quality Assessment for Studies of Diagnostic Accuracy tool was applied to examine the quality of eligible studies, and a bivariate model was used to calculate the pooled estimates. We identified 17 and 10 studies that evaluated the role of OPN alone and OPN combined with CA125 in diagnosing ovarian tumor, respectively. The overall diagnostic sensitivity and specificity of OPN in OC were 0.766 (95 % CI 0.685–0.831) and 0.897 (95 % CI 0.849–0.931), correspondingly. When OPN was combined with CA125, the sensitivity and specificity were 0.871 (95 % CI 0.788–0.924) and 0.881 (95 % CI 0.837–0.914), respectively. OPN is a useful tumor biomarker in future screening tests of OC and can be a promising adjunct to CA125. Additional studies with multicenter trials and carefully selected controls are needed to further verify the results.